Molecular diagnostics: A new frontier in cancer prevention

Expert Review of Molecular Diagnostics

Volumn 4, Issue 4, 2004, Pages 503-511

  Wagner, Paul D ^a   Maruvada, Padma ^a   Srivastava, Sudhir ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer biomarkers; Early detection; Screening; Technology development; Validation

Indexed keywords

BIOLOGICAL MARKER;

CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DNA DETERMINATION; DNA MICROARRAY; EARLY DIAGNOSIS; HUMAN; IMMUNOASSAY; LABORATORY; LASER CAPTURE MICRODISSECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR BIOLOGY; OUTPATIENT DEPARTMENT; PROTEIN ANALYSIS; PUBLICATION; REPRODUCIBILITY; REVIEW; RNA ANALYSIS;

GENOME; HUMANS; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; PROTEOME; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 3142696980     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.4.4.503     Document Type: Review

References (41)

1. Lerman C, Shields AE. Genetic testing for cancer susceptibility: the promise and the pitfalls. Nature Rev. Cancer 4(3), 235-241 (2004).
2. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl Cancer Inst. 95 (17), 1276-1299 (2003).
3. Miller M. 2015: a target date for eliminating suffering and death due to cancer. NCI Bench Marks 3(2), (2003).
4. Etzioni R, Urban N, Ramsey S et al. The case for early detection. Nature Rev. Cancer 3(4), 243-252 (2003). Reviews the impact of early cancer detection on morbidity and mortality.
5. Smith RA, Mettlin CJ, Davis KJ et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J. Clin. 50(1), 34-49 (2000).
6. Ornstein DK, Kang J. How to improve prostate biopsy detection of prostate cancer. Curr. Urol. Rep. 2(3), 218-223 (2001).
7. Ito K, Yamamoto T, Ohi M et al. Natural history of PSA increase with and without prostate cancer Urology 62(1), 64-69 (2003).
8. Li J, Zhang Z, Rosenzweig J et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48(8), 1296-1304 (2002).
9. Ye B, Cramer DW, Skates SJ et al. Haptoglobin-α subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9(8), 2904-2911 (2003). Reports the increased specificity and sensitivity when two biomarkers are used in combination.
10. Pfeil K, Eder IE, Putz T et al. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58(3), 259-268 (2004).
11. Stewart JR, O'Brian CA. Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC α inhibition. Invest. New Drugs 22(2), 107-117 (2004).
12. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell. Biochem. 253(1-2), 89-101 (2003).
13. Kiyama S, Morrison K, Zellweger T et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res. 63(13), 3575-3584 (2003).
14. Lee SO, Lou W, Hou M et al. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 9(1), 370-376 (2003).
15. Macgregor PF, Squire JA. Application of microarrays to the analysis of gene expression in cancer. Clin. Chem. 48(8), 1170-1177 (2002). Microarrays to diagnose and classify cancers.
16. Wong KK, Cheng RS, Mok SC. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 30(3), 670-675 (2001).
17. Zakroff J. Microarrays prove to be effective clinical diagnostic tools. IVD Technology July, 11-12 (2003).
18. Zakroff J. DNA chips enter the clinical market. IVD Technology April, 10-11 (2003).
19. Hacia JG, Sun B, Hunt N et al. Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arrays. Genome Res. 8(12), 1245-1258 (1998).
20. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13), 1671-1679 (2002).
21. Mark Smales C, Birch JR, Racher AJ et al. Evaluation of individual protein errors in silver-stained two-dimensional gels. Biochem. Biophys. Res. Commun. 306(4), 1050-1055 (2003).
22. Resing KA. Analysis of signaling pathways using functional proteomics. Ann. NY Acad Sci. 971, 608-614 (2002).
23. Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J. Cell. Biochem. 91(2), 365-374 (2004).
24. Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnol. 17(10), 994-999 (1999).
25. Wright ME, Eng J, Sherman J et al. Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells. Genome Biol. 5(1), R4 (2003).
26. Vlahou A, Schellhammer PF, Mendrinos S et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158(4), 1491-1502 (2001).
27. Shin BK, Wang H, Hanash S. Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J. Mammary Gland Biol. Neoplasia 7(4), 407-413 (2002).
28. Liotta LA, Espina V, Mehta AI et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3(4), 317-325 (2003).
29. Sreekumar A, Chinnaiyan AM. Protein microarrays: a powerful tool to study cancer. Curr. Opin. Mol. Ther. 4(6), 587-593 (2002).
30. Miller JC, Zhou H, Kwekel J et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3(1), 56-63 (2003).
31. Lal SP, Christopherson RI, dos Remedios CG. Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today 7(Suppl. 18), S143-149 (2002).
32. Chaurand P, Caprioli RM. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis 23(18), 3125-3135 (2002).
33. Jain K. The role of protein-chip technology in molecular diagnostics. IVD Technology July/August, 15-30 (2002).
34. Sullivan Pepe M, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93(14), 1054-1061 (2001). Proposes a five step approach to biomarker validation.
35. Marrero JA, Su GL, Wei W et al. Des-γ carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 37(5), 1114-1121 (2003).
36. Poon TC, Yip TT, Chan AT et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49(5), 752-760 (2003).
37. Mok SC, Chao J, Skates S et al. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl Cancer Inst. 93(19), 1458-1464 (2001).
38. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002). One of the first reports on serum proteomic profiling for cancer detection.
39. Petricoin EF III, Ornstein DK, Paweletz CP et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94(20), 1576-1578 (2002).
40. Kozak KR, Amneus MW, Pusey SM et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc. Natl Acad. Sci. USA 100(21), 12343-12348 (2003).
41. Adam BL, Qu Y, Davis JW et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62(13), 3609-3614 (2002). One of the first reports on serum proteomic profiling for cancer detection.